Kazia Therapeutics Limited (KZIA), an Australian oncology-focused biotechnology company, has reported positive interim data from its ongoing phase II study of Paxalisib in glioblastoma, the most common and most aggressive form of primary brain cancer.
from RTT - Biotech https://ift.tt/39SlBSQ
via IFTTT
No comments:
Post a Comment